TMCnet News

Global Genetic Diseases, Cancer, Forensic & Paternity Molecular Diagnostic Testing Markets Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Abbott, Affymetrix, Biokit - Research and Markets
[March 31, 2016]

Global Genetic Diseases, Cancer, Forensic & Paternity Molecular Diagnostic Testing Markets Report 2016-2020 - Analysis, Technologies & Forecasts - Key Vendors: Abbott, Affymetrix, Biokit - Research and Markets


Research and Markets has announced the addition of the "2016-2020 Global Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets: Country Forecasts, Emerging Technologies, Competitive Strategies" report to their offering.

This new seven-country study from contains 570 pages, 42 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities for molecular diagnostic technologies and products in testing for genetic diseases, cancer, as well as forensic and paternity/HLA typing applications during the next five years.

Key Topics Covered:

  • Market shares of leading suppliers
  • Business and technological trends in major markets
  • Five-year test volume and sales forecasts
  • Market shares of leading competitors
  • Feature comparison of major analyzers
  • Strategic profiles of leading market players and start-up firms developing innovative products
  • Specific prodct and business opportunities for instrument and consumable suppliers.



Genetic Diseases, Cancer, Forensic and Paternity molecular diagnostic testing markets are among the most rapidly growing segments of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by these markets, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies.

Contains 570 pages and 42 tables


Companies Mentioned Include:

  • Abbott
  • Affymetrix
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher (News - Alert)
  • Becton Dickinson
  • Biokit
  • bioMerieux
  • Bio-Rad
  • Kreatech/Leica
  • Li-Cor Biosciences
  • Monogram Biosciences/LabCorp
  • Myriad Genetics
  • Ortho-Clinical Diagnostics
  • Perkin Elmer/Caliper
  • Proteome Sciences
  • Qiagen
  • Roche
  • Scienion
  • Sequenom
  • Shimadzu
  • Siemens (News - Alert)
  • Sierra Molecular
  • Takara Bio
  • Tecan Group
  • Thermo Fisher

For more information visit http://www.researchandmarkets.com/research/zptl6j/20162020_global


[ Back To TMCnet.com's Homepage ]